Table 1 Patient characteristics.

From: Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients

 

All patients

Initial response

Disease progression

Total number of cases

52

30

28

Sex

 Male

15

8

9

 Female

37

22

19

Age

 <49

7

4

7

 50–59

8

5

4

 60–69

18

12

8

 70–79

17

7

8

 80–89

2

2

1

Stage

 IIIA

4

3

3

 IIIB

7

5

2

 IV

41

22

23

Mutation in biopsy sample

 exon 19 deletion

26

15

16

 L858R

23

14

11

 double

1

0

0

 L861Q

1

1

1

 G719C

1

0

0

Treatment before EGFR-TKI

 none

25

15

15

 surgery

3

1

3

 surgery/radiation

6

4

2

 surgery/chemotherapy

3

1

3

 radiation

7

5

2

 radiation/chemotherapy

4

1

2

 chemotherapy

4

3

1

EGFR-TKI

 gefitinib

41

22

24

 erlotinib

11

8

4

Effect of EGFR-TKI

 complete response (CR)

2

1

1

 partial response (PR)

36

23

22

 stable disease (SD)

7

1

2

 progressive disease (PD)

3

3

0

 not evaluable (NE)

4

2

3

Back to article page